Clinical experience across the fetal-fraction spectrum for a non-invasive prenatal screen with low test-failure rate.
To describe the clinical experience across the entire range of fetal-fraction measurements for a noninvasive prenatal screen (NIPS) that uses whole genome sequencing (WGS). We retrospectively analyzed results from 58,105 patients who underwent NIPS on a customized WGS platform during an eight-month period and assessed clinical test performance for trisomy 21, trisomy 18, and trisomy 13 in singleton pregnancies. Pregnancy outcomes were sought for all screen-positive patients and for 18% of screen-negative patients. The screen yielded a result for 99.9% of patients, meaning that approximately 1 in 1000 patients received a test failure. 572 pregnancies (1%) screened positive for common aneuploidies (362 with trisomy 21, 142 with trisomy 18, and 68 with trisomy 13). Informative outcomes were received for 237 (41.4%) screen-positive results and 3,258 (6.0%) screen-negative results. In the full cohort, inferred sensitivities for trisomy 21, trisomy 18, and trisomy 13 were 99.7%, 96.8%, and 94.3%, respectively, and positive predictive values were 93.1%, 85.2%, and 48.4%, respectively. If a fetal-fraction threshold of 4% had been employed to guard against false negatives, calculated sensitivities for the three aneuploidies would not change significantly, yet, importantly, the overall test-failure rate would increase to 6.6% (n=3,829), impacting 1 in 15 women. Our clinical experience demonstrates that a customized WGS-based NIPS without a fetal-fraction threshold achieves high accuracy while maintaining a low test-failure rate of 0.1%. As such, alternative strategies to ensure high accuracy for common aneuploidies at low fetal fraction-e.g., test failure, redrawing at a later gestational age, risk scoring based on fetal fraction-are not necessary for this screen. This article is protected by copyright. All rights reserved.